share_log

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

Benzinga Real-time News ·  Jun 22, 2022 06:40
  • Galapagos (NASDAQ:GLPG) agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities.
  • Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio. 
  • Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform.
  • Related: RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value.
  • The deal aims for three next-generation CAR-Ts to the clinic over the next three years.
  • CellPoint has developed a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies and avoids complex logistics. 
  • The proprietary platform consists of CellPoint's end-to-end xCellit workflow management and monitoring software and Lonza Group's (OTC:LZAGF) Cocoon system, a closed, automated manufacturing platform for cell and gene therapies.
  • Price Action: GLPG shares are down 1.91% at $54.93 during the premarket session on the last check Wednesday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment